Nurix Therapeutics, Inc. (NRIX)
After hours:
| Previous Close | 24.72 |
| Open | 24.68 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 24.65 - 25.83 |
| 52 Week Range | 4.22 - 26.43 |
| Volume | |
| Avg. Volume | 693,237 |
| Market Cap | 1.774B |
| Beta (5Y Monthly) | 2.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.90 |
| Earnings Date | Oct 11, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30.64 |
GlobeNewswireNurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom’s Macroglobulinemia
NX-5948 demonstrated robust clinical activity with objective responses observed in 7 of 9 (77.8%) evaluable Waldenstrom’s patients in the ongoing Phase 1a/1b clinical trial Responses are durable and deepen over time with two patients on treatment for greater than one year Data were presented at the 12th International Workshop on Waldenstrom’s Macroglobulinemia (IWWM-12) SAN FRANCISCO, Oct. 19, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical co
- GlobeNewswire
Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur
SAN FRANCISCO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced the appointment of Anil Kapur to its board of directors, effective October 15, 2024. Mr. Kapur has over 25 years of executive experience in pharmaceutical and biotech companies across both U.S. and international markets. “I am delighted to
